Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.
Also called NCT06187727
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 248 participants
- Sponsor
- Qian geng
- Registry
-
NCT06187727
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06187727. Randomized; double masking; primary purpose treatment. Start 2023-07-01 (actual); primary completion 2025-01-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction
- Acronym
- Health
- Condition
- Myocardial Infarction
- Condition
- Heart Failure
- Intervention (Drug)
- Henagliflozin
- Lead sponsor
- Qian geng
Record details
- Record id
cardio:ct-nct06187727- Content hash
d8d6f223a79d0ac51f46fd7f87b859d7e888a81a9b393ba97b86c10ab0757af8